BD Revolutionizes At-Home HPV Testing
BD (Becton, Dickinson and Company) (NYSE: BDX), a renowned global leader in medical technology, has unveiled a pioneering self-collection solution aimed at enhancing HPV testing. This innovative approach is specifically designed for markets outside of the United States, thereby simplifying the at-home sample collection process.
With this latest technology, patients can easily collect samples without needing complex devices or liquids, making the process non-invasive and user-friendly. Ending the logistical barriers surrounding traditional sample collection, the BD COR™ System also facilitates mailing samples directly to the lab, streamlining the entire workflow.
Streamlined Laboratory Processing
The advanced self-collection swab has received certification under the In Vitro Diagnostic Medical Device Regulation (IVDR) in Europe, a noteworthy achievement recognized by various countries globally. This technology simplifies laboratory processes by eliminating manual preparation required for samples. Clinical laboratory technicians can now allocate their time to more critical tasks, improving overall lab efficiency.
Once self-collected, samples are automatically processed using robotic technology, ensuring a seamless transition from collection to reporting results. The internal cellular control and minimal human interaction involved in the process guarantee the quality and reliability of the results.
Significant Advancements in Screening Accessibility
Nikos Pavlidis, worldwide president of BD Diagnostic Solutions, emphasized the importance of this innovation, noting that it significantly advances efforts to broaden access to cervical cancer screening worldwide. Pavlidis stated that this automated method not only enhances laboratory efficiency but also encourages participation in screening programs, enabling individuals to do so from their own homes.
Key Features of the New Self-Collection Solution
This groundbreaking IVDR-certified workflow boasts several remarkable features:
- Onboard Rehydration Technology which removes the need for manual sample preparation.
- A safe and dry self-collection process without requiring chemicals or liquids.
- An intuitive and patient-friendly sample collection and mailing process.
- Stability of dry samples for up to 30 days, including resistance to higher temperatures and several freeze/thaw cycles.
- A unified workflow driven by barcoding for both clinician-collected and self-collected samples.
- The proven success and reliability of the Copan FLOQSwab®.
Future Availability
The BD Onclarity™ HPV Self-Collection with Onboard Rehydration Fully Automated Solution is on track to launch in IVDR-recognized markets soon, endorsing public health initiatives that aim to expand access to essential cervical cancer screenings. This solution not only supports women’s health but also fosters the growth of laboratories looking to improve the overall efficiency of their services.
About BD
BD stands as one of the largest medical technology firms globally, committed to propelling advancements in health through innovations in medical discovery and diagnostics. With over 70,000 dedicated employees, BD develops cutting-edge technologies to enhance the safety and efficiency of healthcare delivery. This commitment extends worldwide as BD collaborates closely with partners to address challenging global health issues, ensuring improvements in outcomes while lowering costs and enhancing efficiency.
Frequently Asked Questions
What is BD's latest innovation in HPV testing?
BD has developed a new self-collection solution for HPV testing designed for use in various markets outside of the United States, allowing easier patient sample collection.
How does this new testing technology work?
This technology simplifies at-home sample collection without the necessity of complex devices or liquids, making it safe and non-invasive for patients.
What are the benefits of the BD COR™ System?
The BD COR™ System automates laboratory processing, enhancing efficiency and allowing technicians to focus on more important tasks, leading to quicker results.
Where will this new HPV self-collection solution be available?
The BD Onclarity™ HPV Self-Collection solution is expected to become available in several IVDR-recognized markets globally in the near future.
Why is the IVDR certification significant for BD's new product?
IVDR certification assures that the product complies with strict European regulations, enhancing its recognition and acceptance in various healthcare markets worldwide.
